AstraZeneca has agreed to invest $2 billion in Summit Therapeutics, a US cancer drug specialist, as part of a collaboration on cancer treatments, according to The Wall Street Journal, The Times and Independent Journal Review.
The Times reported that the investment gives AstraZeneca a stake in Summit Therapeutics.
Separately, the South China Morning Post reported that deals involving AstraZeneca, Merck and Novo Nordisk have added fresh momentum to the Chinese biotech sector, though it did not specify how the Summit Therapeutics deal relates to Chinese biotech activity.
Details on the specific cancer drugs involved in the AstraZeneca-Summit collaboration were not specified in the available reporting.
How each side covered it
Center
- The Wall Street Journal reported AstraZeneca will invest $2 billion in Summit Therapeutics to collaborate on cancer drugs.
- The South China Morning Post connected the deal to broader momentum in Chinese biotech, alongside separate deals involving Merck and Novo Nordisk.
“AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs” — The Wall Street Journal
Right
- The Times reported AstraZeneca is taking a $2 billion stake in Summit Therapeutics, described as a US cancer specialist.
- Independent Journal Review reported the $2 billion investment as part of a cancer drug partnership.
“AstraZeneca takes $2bn stake in US cancer specialist” — The Times
Questions readers ask
What did AstraZeneca announce?
AstraZeneca announced a $2 billion investment in Summit Therapeutics, a US cancer drug specialist, to collaborate on developing cancer drugs, according to The Wall Street Journal, The Times and Independent Journal Review.
What does AstraZeneca get from the deal?
According to The Times, AstraZeneca takes a stake in Summit Therapeutics as part of the $2 billion investment.
How does this relate to Chinese biotech?
The South China Morning Post reported that this deal, along with separate deals involving Merck and Novo Nordisk, has added fresh momentum to the Chinese biotech sector, though the exact connection was not detailed.
What did left- and right-leaning outlets focus on?
No left-leaning coverage was available. Right-leaning outlets, including The Times and Independent Journal Review, focused on the $2 billion investment and AstraZeneca's stake in Summit Therapeutics.
Sources · 4 outlet reports
- South China Morning PostCenterAstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech
- The Wall Street JournalCenterAstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
- Independent Journal ReviewRight-leaningAstraZeneca invests $2 billion in Summit cancer drug partnership
- The TimesRight-leaningAstraZeneca takes $2bn stake in US cancer specialist